Welcome
Our medical technologies drive results
Our SARS-CoV-2 assays for both our Panther® and Panther Fusion® systems enable labs to run over 1000 tests in 24 hours and attain first results in 3.5 hours or less.*
Note
Number of actual test results per day may vary based on individual lab practices and workflows.
Panther Scalable Solutions allows you to expand your testing menu while adding flexibility, capacity and walkaway time. Consolidate your molecular testing today and meet your lab’s growing needs tomorrow.
To date, over 3 million women have been treated with the NovaSure procedure.1 For 77.7% of women, menstrual bleeding is successfully reduced or stopped within one year.2
References and Important Safety Information
1. Hologic, Inc. Data on file;2018. 2. NovaSure Instructions for Use.
Important Safety Information: NovaSure® endometrial ablation is for premenopausal women with heavy periods due to benign causes who are finished childbearing. Pregnancy following the NovaSure procedure can be dangerous. The NovaSure procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. NovaSure endometrial ablation is not a sterilization procedure. Rare but serious risks include, but are not limited to, thermal injury, perforation and infection. Temporary side effects may include cramping, nausea, vomiting, discharge and spotting. Inform patients to contact you if they experience a possible side effect related to use of this product. For detailed benefit and risk information, please consult the IFU.
The Fluent system’s intuitive operation can streamline hysteroscopic procedures for your entire OR team.
Important Safety Information
The Fluent fluid management system is intended to provide liquid distention of the uterus during diagnostic and operative hysteroscopy, and to monitor the volume differential between the irrigation fluid flowing into and out of the uterus while providing drive, control, and suction for hysteroscopic morcellators.
The Fluent fluid management system may not be used to introduce fluids into the uterus when hysteroscopy is contraindicated. The system should not be used to remove pathologies from pregnant patients or patients exhibiting pelvic infection, cervical malignancies, or previously diagnosed endometrial cancer. For detailed benefit and risk information, including contraindications relative to endometrial ablation, please consult the IFU.
Three sheaths giving you the convenience of seeing and treating pathology with a single hysteroscope. Greater patient comfort and easier insertion with small diameter sheaths.
Important Safety Information
The Omni™ hysteroscope is intended to provide viewing of the cervical canal and uterine cavity for the purpose of performing diagnostic and operative procedures. The Omni hysteroscope is not appropriate for patients who are exhibiting acute pelvic inflammatory disease or exhibitthe following conditions: inability to distend uterus, cervical stenosis, cervical/vaginal infection, uterine bleeding or menses, invasive carcinoma of the cervix, recent uterine perforation, medical contraindications, or intolerance to anesthesia. For detailed benefit and risk information, consult the IFU.
The Panther Fusion system represents the power of diagnostic precision and automation. Experience the combined flexibility of PCR and TMA true sample-to-result automation.
Our breakthrough breast stabilization system – available only on our Dimensions® family of mammography systems* – delivers a clinically proven, more comfortable patient experience.
Reference
* FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005
1. Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00119 Rev 003 (2017).
Discover Hologic's ultrasound system for breast imaging, designed to help increase efficiency and diagnostic accuracy. It offers excellent image quality, innovative imaging modes (ShearWave™ PLUS elastography, TriVu™ imaging, Needle PLUS™ imaging) and ultimate usability.
Reference
* Ultrafast Ultrasound Imaging, by Jeremy Bercoff (Published: August 23rd 2011 DOI: 10.5772/19729)
